TrilliumBiO and Oncobit Unveil New Monitoring Solution for Uveal Melanoma in the U.S.
In a significant advancement in cancer diagnostics, TrilliumBiO, renowned for its expertise in biomarker discovery and precision diagnostics, has partnered with the Swiss-based company Oncobit to introduce Oncular™, a state-of-the-art uveal melanoma monitoring solution in the United States. This innovative test aims to enhance patient management for those affected by uveal melanoma, a rare and often overlooked form of eye cancer.
Oncular™ leverages Oncobit’s proprietary technology to provide a real-time assessment of circulating tumor DNA (ctDNA) through a simple blood test. This approach not only underscores the potential for personalized cancer care but also addresses the limitations of traditional monitoring methods, which predominantly rely on imaging techniques and non-specific blood markers. By implementing a combination of digital PCR techniques and cloud-based analysis, Oncular™ offers sensitive and reproducible results, making it a valuable tool for clinicians across the country.
“One of the challenging aspects of managing uveal melanoma is the navigation towards informed treatment decisions. Oncular™ enhances this process by providing clinicians with precise molecular monitoring insights,” stated Laura Vivian, CEO of TrilliumBiO. “Our collaboration with Oncobit reflects our commitment to transforming how patients experience their cancer journey through innovative diagnostics.”
The Oncular™ test measures several critical indicators essential for effective patient management: 1) Molecular Residual Disease (MRD) status; 2) Longitudinal trends in ctDNA, and 3) Early detection signals of treatment response or disease progression. Research utilizing Oncobit’s technology suggests that variations in ctDNA can effectively predict treatment outcomes and disease advancement in cases of metastatic uveal melanoma, reinforcing the clinical relevance of this testing approach.
Dr. Claudia Scheckel, CEO of Oncobit, expressed excitement about the test's U.S. launch, emphasizing its role in elevating access to sophisticated molecular testing for this rare cancer type. He remarked, “The rollout of Oncular™ signifies an important step forward in providing healthcare professionals with essential resources for better disease understanding and patient care.”
TrilliumBiO’s extensive laboratory capabilities ensure that Oncular™ is both cost-effective and scalable for routine clinical application while maintaining high standards of quality through CLIA certification and CAP accreditation. The platform facilitates a seamless integration of Oncobit’s testing protocols with TrilliumBiO’s entrenched diagnostic infrastructure.
As the healthcare community advances towards more personalized cancer therapies, the introduction of Oncular™ stands out as a promising solution. It aims to reduce the time, expense, and invasiveness often associated with traditional monitoring. Both companies are focused on improving clinical outcomes and supporting clinicians in making informed, evidence-based decisions for their patients.
Interested healthcare providers can learn more about ordering Oncular™ or its availability by visiting the official TrilliumBiO website or contacting their customer service. The future of uveal melanoma management is evolving, and with solutions like Oncular™, patients are at the heart of these advancements, providing hope for more effective monitoring and treatment.
For TrilliumBiO, headquartered just outside Washington D.C., the launch of Oncular™ not only signifies a milestone in its ongoing dedication to enhancing patient care but also highlights its significant role in the rapidly growing sector of precision oncology. By connecting innovative scientific discoveries to real-world diagnostics, TrilliumBiO maintains a commitment to improving the lives of those affected by rare diseases.
Oncular™ leverages Oncobit’s proprietary technology to provide a real-time assessment of circulating tumor DNA (ctDNA) through a simple blood test. This approach not only underscores the potential for personalized cancer care but also addresses the limitations of traditional monitoring methods, which predominantly rely on imaging techniques and non-specific blood markers. By implementing a combination of digital PCR techniques and cloud-based analysis, Oncular™ offers sensitive and reproducible results, making it a valuable tool for clinicians across the country.
“One of the challenging aspects of managing uveal melanoma is the navigation towards informed treatment decisions. Oncular™ enhances this process by providing clinicians with precise molecular monitoring insights,” stated Laura Vivian, CEO of TrilliumBiO. “Our collaboration with Oncobit reflects our commitment to transforming how patients experience their cancer journey through innovative diagnostics.”
The Oncular™ test measures several critical indicators essential for effective patient management: 1) Molecular Residual Disease (MRD) status; 2) Longitudinal trends in ctDNA, and 3) Early detection signals of treatment response or disease progression. Research utilizing Oncobit’s technology suggests that variations in ctDNA can effectively predict treatment outcomes and disease advancement in cases of metastatic uveal melanoma, reinforcing the clinical relevance of this testing approach.
Dr. Claudia Scheckel, CEO of Oncobit, expressed excitement about the test's U.S. launch, emphasizing its role in elevating access to sophisticated molecular testing for this rare cancer type. He remarked, “The rollout of Oncular™ signifies an important step forward in providing healthcare professionals with essential resources for better disease understanding and patient care.”
TrilliumBiO’s extensive laboratory capabilities ensure that Oncular™ is both cost-effective and scalable for routine clinical application while maintaining high standards of quality through CLIA certification and CAP accreditation. The platform facilitates a seamless integration of Oncobit’s testing protocols with TrilliumBiO’s entrenched diagnostic infrastructure.
As the healthcare community advances towards more personalized cancer therapies, the introduction of Oncular™ stands out as a promising solution. It aims to reduce the time, expense, and invasiveness often associated with traditional monitoring. Both companies are focused on improving clinical outcomes and supporting clinicians in making informed, evidence-based decisions for their patients.
Interested healthcare providers can learn more about ordering Oncular™ or its availability by visiting the official TrilliumBiO website or contacting their customer service. The future of uveal melanoma management is evolving, and with solutions like Oncular™, patients are at the heart of these advancements, providing hope for more effective monitoring and treatment.
For TrilliumBiO, headquartered just outside Washington D.C., the launch of Oncular™ not only signifies a milestone in its ongoing dedication to enhancing patient care but also highlights its significant role in the rapidly growing sector of precision oncology. By connecting innovative scientific discoveries to real-world diagnostics, TrilliumBiO maintains a commitment to improving the lives of those affected by rare diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.